1. Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic ductal adenocarcinoma
- Author
-
Aoi Hayasaki, Yasuhiro Murata, Shugo Mizuno, Daisuke Noguchi, Akihiro Tanemura, Naohisa Kuriyama, Shuji Isaji, Masashi Kishiwada, Hiroyuki Sakurai, Katsunori Uchida, Yusuke Iizawa, Kazuyuki Gyoten, and Takehiro Fujii
- Subjects
medicine.medical_specialty ,Radiosensitizer ,Pancreatic ductal adenocarcinoma ,CA-19-9 Antigen ,Endocrinology, Diabetes and Metabolism ,Histological response ,Adenocarcinoma ,Gastroenterology ,Internal medicine ,medicine ,Humans ,Clinical significance ,In patient ,Retrospective Studies ,R0 resection ,Preoperative chemoradiotherapy ,Hepatology ,business.industry ,Chemoradiotherapy ,Prognosis ,Gemcitabine ,Pancreatic Neoplasms ,business ,Carcinoma, Pancreatic Ductal ,medicine.drug - Abstract
The clinical value and predictors of a favorable histological response to preoperative chemoradiotherapy (CRT) in pancreatic ductal adenocarcinoma (PDAC) remains undefined.To assess the significance and predictors of a favorable histological response to preoperative CRT in patients with localized PDAC.The study included 203 patients with localized PDAC undergoing curative-intent resection after CRT. The rate of R0 resection and overall survival (OS) and recurrence-free survival (RFS) were correlated with the grading of histological response to determine optimal stratification. Clinical factors associated with a significant histological response were evaluated using multivariate regression analysis.Among all patients, eight patients (3.9%) had a grade 4 (pCR); 40 (19.4%) had a grade 3 estimated rate of residual neoplastic cells10% (near-pCR); and 155 (76.7%) had a grade 1/2 limited response. The 48 patients with pCR/near-pCR achieved significantly higher R0 resection rate (100%) than those with grade 1/2 (80.0%). The 5-year OS and RFS rates were significantly higher in the patients with pCR/near-pCR (45.3% and 36.5%) than in those with grade 1/2 (27.1% and 18.5%). Gemcitabine plus S-1 based CRT, serum CA19-9 level after CRT83 U/mL, and interval from initial treatment to surgery ≥4.4 months were independent predictive factors for pCR/near-pCR.pCR or near-pCR to preoperative CRT contributed to achieving a high rate of R0 resection and improving survival for localized PDAC. The use of gemcitabine plus S-1 as a radiosensitizer, lower serum CA19-9 level after CRT, and longer preoperative treatment duration were significantly associated with pCR or near-pCR.
- Published
- 2021
- Full Text
- View/download PDF